Latest News

Big multiple sclerosis breakthrough: Phase 1 trial safely resets patients' immune systems and reduces attack on myelin protein

A phase 1 clinical trial for the first treatment to reset the immune system of multiple sclerosis (MS) patients showed the therapy was safe and dramatically reduced patients' immune systems' reactivity to myelin by 50 to 75 percent. The therapy used billions of patients' own specially processed blood cells to create tolerance to myelin, the insulating layer that forms around nerves. In MS, the immune system attacks myelin. The approach left the normal immune system intact.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • Cocaine addiction, craving and relapse

  • On-demand X-rays at synchrotron light sources

  • How racial stereotypes impact the way we communicate

  • Breakthrough measures Parkinson's progression in brain

  • Study identifies possible role for carbon monoxide in treating hemorrhagic stroke

  • Moderate drinking in later years may damage heart

  • Nanotechnology identifies brain tumor types through MRI 'virtual biopsy' in animal studies

  • Study examines association of genetic variants with cognitive impairment

  • Hospice use linked to fewer depressive symptoms for surviving spouses

  • Where there's a will ? well, there's another way

  •